Clinical and Translational Science Institute

The Ohio State University Clinical and Translational Science Institute (CTSI) is a collaboration among the University, The Ohio State University Wexner Medical Center and Nationwide Children's Hospital dedicated to turning the scientific discoveries of today into life-changing disease prevention strategies and the health diagnostics and treatments of tomorrow.

Funded by a multi-year Clinical and Translational Science Award (CTSA) from the National Institutes of Health, the CTSI leverages expertise from all participants, community health and education agencies, business partnerships, and regional institutional network partnerships.

Leadership

  • Director and Principal Investigator: Julie Johnson, PharmD (The Ohio State University College of Medicine)
  • Pediatric Director and Multiple Principal Investigator: Cynthia Gerhardt, PhD (Clinical and Translational Science Institute, Center for Biobehavioral Health, the Abigail Wexner Research Institute at Nationwide Children's Hospital)
  • Deputy Director: Henry Wang, MD, MS (The Ohio State University College of Medicine)

History

In 2008, the NIH awarded a $34-million, five-year CTSA grant to The Ohio State University – along with Nationwide Children’s Hospital – to fund the CTSI. Among the largest research grants in the University’s history, the CTSA award was a team effort based on the clinical and translational research enterprise, training programs, informatics capabilities, trans-disciplinary collaborations and partnerships with private and public organizations. In 2013, the NIH awarded a $25.4 million grant to the CTSI to continue accelerating basic science discoveries into life-saving medical advances.

“Ohio State and Nationwide Children’s campuses have significantly invested in expanding our translational research capabilities," said Joanne Turner, PhD, BSc, chief scientific officer of the Abigail Wexner Research Institute at Nationwide Children’s. "This commitment has led to major breakthroughs, especially in gene therapy for severe and debilitating muscular diseases. Our collaboration is providing new insights into the continuum of care as children with chronic diseases transition into adulthood, and it is opening up new possibilities for disease prevention."

Core Services at Nationwide Children's Hospital

Relevant Links